PluroGen Therapeutics, Inc.
503 Broadleaf Way
Charlottesville, VA 22911
Tel: 443 994 0101
Fax: 410 990 9817
www.plurogen.com
503 Broadleaf Way
Charlottesville, VA 22911
Tel: 443 994 0101
Fax: 410 990 9817
www.plurogen.com
| News Release |
FOR IMMEDIATE RELEASE Contact: Neal G. Koller
President & CEO
27 June 2008 Board of Directors
443 994 0101
PLUROGEN THERAPEUTICS INC. SIGNS LETTER OF INTENTWITH PNG GEROLYMATOS SA TO
COMMERCIALIZE PLUROGEN PRODUCTS IN THE US AND EUROPE
(Charlottesville, VA, 27 June 2008) – PluroGen Therapeutics, Inc. today announced the signing of a Letter
of Intent with PNG Gerolymatos SA (Athens, Greece) for the companies to enter the US and European OTC
and cosmetic markets through development and commercialization of new products based on PluroGen’s
proprietary gel technology and for PNG Gerolymatos to distribute PluroGen branded products in several
countries.
Commenting on the Letter of Intent, Neal G. Koller, President & CEO of PluroGen, said, “PNG Gerolymatos
has an extensive sales, marketing and distribution network in key global markets including US and major
European countries. In the US alone, Gerolymatos reaches into 25,000 drug stores. Selling our products
through multiple Gerolymatos divisions is a very strategic step forward for PluroGen. Gerolymatos interest
in PluroGen further confirms the value of our products and the significant cross-market opportunities for
our technology platforms. We are looking forward to a successful relationship.”
Alberto Manouach, PhD, Executive Vice President Business Development for PNG Gerolymatos, commented
that “PluroGen provides Gerolymatos with a broad range of very exciting new products across several of
our business units including our OTC, pharmaceutical, cosmetic and animal health divisions. We look
forward to introducing products with PluroGen. The relationship will be a good one for both companies”.
About PluroGen Therapeutics, Inc.
PluroGen is a wound healing company commercializing its patent-protected gel technology platform that
provides superior and differentiated physical and bio-impact benefits to wound healing. The technology is
configurable to deliver drug and non-drug compounds as protected and advanced therapeutic products for
simple and complex wound healing. PluroGen’s product pipeline targets improved, protected therapies for
the 6 areas of treatment in tissue healing (cleansing, infection, pain, inflammation, tissue salvage, tissue
regeneration).
PluroGen’s first gel, PluroGel™, is being used initially in skin and wound cleansing products and for two
branded topical antimicrobial products, PluroGel™ Silver Sulfadiazine and PluroGel™ TAG. PluroGel™ TAG is
currently in routine use at the University of Virginia Medical Center, having shown superior results on more
than 2,000 patients in two different patient populations, severe burns and chronic wounds. The PluroGen
management and operational teams, Boards and Principal Investigators are recognized global clinical and
commercial leaders in PluroGen’s target markets of burn and wound care and in the life sciences industry.
For more information about PluroGen Therapeutics, Inc., visit the Company’s web site at www.plurogen.com.
About PNG Gerolymatos SA
PNG Gerolymatos SA is a health and beauty company with operations in pharmaceuticals, OTC’s, cosmetics,
consumer products, diagnostics and animal health. The company is headquartered in Greece and has
subsidiaries in the USA, France, Italy, Turkey, Slovenia and Hong Kong. Through its subsidiaries and
distribution network PNG Gerolymatos has a presence in over 45 countries. The company sells its own
proprietary products including Breath AgainTM with SinomarinTM, EARrinse with SinomarinTM and FolteneTM
and has distribution rights with a number of multinational companies.
For more information about PNG Gerolymatos SA, visit the Company’s web site at www.gerolymatos.com.
Statements included in this press release that are not historical in nature are "forward-looking statements"
within the meaning of the Private Securities Litigation Reform Act of 1995. The Company cautions readers that
forward-looking statements are subject to certain risks and uncertainties, which could cause actual results to
differ materially and which are identified from time to time in the Company’s reports filed with the U.S.
Securities and Exchange Commission. PluroGen Therapeutics, Inc. claims the protection of the Safe Harbor for
forward-looking statements contained in the Private Securities Litigation Reform Act of 1995.
Information included on PluroGen Therapeutics, Inc website or PNG Gerolymatos SA website is not incorporated herein by
reference or otherwise.
President & CEO
27 June 2008 Board of Directors
443 994 0101
PLUROGEN THERAPEUTICS INC. SIGNS LETTER OF INTENTWITH PNG GEROLYMATOS SA TO
COMMERCIALIZE PLUROGEN PRODUCTS IN THE US AND EUROPE
(Charlottesville, VA, 27 June 2008) – PluroGen Therapeutics, Inc. today announced the signing of a Letter
of Intent with PNG Gerolymatos SA (Athens, Greece) for the companies to enter the US and European OTC
and cosmetic markets through development and commercialization of new products based on PluroGen’s
proprietary gel technology and for PNG Gerolymatos to distribute PluroGen branded products in several
countries.
Commenting on the Letter of Intent, Neal G. Koller, President & CEO of PluroGen, said, “PNG Gerolymatos
has an extensive sales, marketing and distribution network in key global markets including US and major
European countries. In the US alone, Gerolymatos reaches into 25,000 drug stores. Selling our products
through multiple Gerolymatos divisions is a very strategic step forward for PluroGen. Gerolymatos interest
in PluroGen further confirms the value of our products and the significant cross-market opportunities for
our technology platforms. We are looking forward to a successful relationship.”
Alberto Manouach, PhD, Executive Vice President Business Development for PNG Gerolymatos, commented
that “PluroGen provides Gerolymatos with a broad range of very exciting new products across several of
our business units including our OTC, pharmaceutical, cosmetic and animal health divisions. We look
forward to introducing products with PluroGen. The relationship will be a good one for both companies”.
About PluroGen Therapeutics, Inc.
PluroGen is a wound healing company commercializing its patent-protected gel technology platform that
provides superior and differentiated physical and bio-impact benefits to wound healing. The technology is
configurable to deliver drug and non-drug compounds as protected and advanced therapeutic products for
simple and complex wound healing. PluroGen’s product pipeline targets improved, protected therapies for
the 6 areas of treatment in tissue healing (cleansing, infection, pain, inflammation, tissue salvage, tissue
regeneration).
PluroGen’s first gel, PluroGel™, is being used initially in skin and wound cleansing products and for two
branded topical antimicrobial products, PluroGel™ Silver Sulfadiazine and PluroGel™ TAG. PluroGel™ TAG is
currently in routine use at the University of Virginia Medical Center, having shown superior results on more
than 2,000 patients in two different patient populations, severe burns and chronic wounds. The PluroGen
management and operational teams, Boards and Principal Investigators are recognized global clinical and
commercial leaders in PluroGen’s target markets of burn and wound care and in the life sciences industry.
For more information about PluroGen Therapeutics, Inc., visit the Company’s web site at www.plurogen.com.
About PNG Gerolymatos SA
PNG Gerolymatos SA is a health and beauty company with operations in pharmaceuticals, OTC’s, cosmetics,
consumer products, diagnostics and animal health. The company is headquartered in Greece and has
subsidiaries in the USA, France, Italy, Turkey, Slovenia and Hong Kong. Through its subsidiaries and
distribution network PNG Gerolymatos has a presence in over 45 countries. The company sells its own
proprietary products including Breath AgainTM with SinomarinTM, EARrinse with SinomarinTM and FolteneTM
and has distribution rights with a number of multinational companies.
For more information about PNG Gerolymatos SA, visit the Company’s web site at www.gerolymatos.com.
Statements included in this press release that are not historical in nature are "forward-looking statements"
within the meaning of the Private Securities Litigation Reform Act of 1995. The Company cautions readers that
forward-looking statements are subject to certain risks and uncertainties, which could cause actual results to
differ materially and which are identified from time to time in the Company’s reports filed with the U.S.
Securities and Exchange Commission. PluroGen Therapeutics, Inc. claims the protection of the Safe Harbor for
forward-looking statements contained in the Private Securities Litigation Reform Act of 1995.
Information included on PluroGen Therapeutics, Inc website or PNG Gerolymatos SA website is not incorporated herein by
reference or otherwise.